1.Relationship between the serum level of β2-microglobin and international prognostic index and the prognostic analysis of patients with peripheral T-cell lymphoma
Zhanhe PAN ; Huiqiang HUANG ; An SU ; Xin WANG ; Qingqing CAI ; Yan GAO ; Xia LU
Journal of Leukemia & Lymphoma 2012;21(9):528-530
Objective To determine the relationship between the serum level of β2-microglobin (β2-MG)and international prognostic index (IPI) and investigate the role of IPI in predicting the prognosis and making individualized therapy for peripheral T-cell lymphoma (PTCL).Methods Eighty-one patients with PTCL were treated by standard CHOP regimen.The clinical characteristics,response,long-term surival rates and the relationship between serum level of β2-MG and IPI scores were analyzed retrospectively.Results Eighty-one patients were eligible.All of them were treated by CHOP regimen.The overall response rate (RR) was 82.7 % with 53.1% complete remission (CR) rate.The RR of IPI low risk,low-intermediate risk,high-intermediate risk,and high risk were 95.7 %,87.5 %,53.8 % and 20.0 %,with CR rate 74.5 %,37.5 %,15.4 % and 0,respectively (P <0.05).The median survival times (MST) were 31.2 months at a median follow-up of 30 months (2-98 months).The acturial 1-,3-,and 5-year overall survival (OS) rates were 83.5 %,41.8 % and 34.7 %,respectively.The 5-year OS rates of low risk,low-intermediate risk,high-intermediate risk,high risk were 57.3 %,55.9 %,0 and 0,respectively (P <0.05).The OS rates of low risk group (IPI 0-2 scores) and high risk group (IPI 3-5 scores) were 54.8 % and 0,respectively (P <0.05).Serum levels of β2-MG were significantly elevated in the high risk group than those in the low risk group.The proportion of abnormal serum level of [β2-MG were also significantly elevated in the high risk group than those in the low risk group.The results of multivariante analysis showed that serum level of β2-MG and IPI scores were independent prognostic factors for PTCL (P<0.05).Conclusion The serum level of β2-MG with IPI scores system can be uscd for evaluating the prognosis of PTCL patients.
2. Mechanism of celecoxib reverses adriamycin resistance in NK/T cell lymphoma cells by Notch 1/NF-κB/STAT3 pathway
Zhanhe PAN ; Xin WANG ; An SU ; Peng ZHANG ; Haonan JI ; Xiaomei WANG
Chinese Journal of Clinical Pharmacology and Therapeutics 2020;25(12):1330-1336
AIM: To observe the mechanism of celecoxib reversal adriamycin resistance in NK/T cell lymphoma cells. METHODS: SNK6 and SNK6/ADR cells were treated with celecoxib of different concentrations (10, 20, 40, 60, 80, 100 μmol/L), the growth inhibition rate of SNK6 and SNK6/ADR were measured by MTT method. The IC